Related Experiment Video

Updated: Feb 1, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K

First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?

Pamela Abdayem1, Claudia Parisi1, David Planchard2,3

  • 1Département de médecine oncologique, Gustave Roussy, 114 Edouard Vaillant Street, 94805, Villejuif Cedex, France.

Drugs
|January 31, 2026
PubMed

Insights

First-line combination therapies for EGFR-mutated non-small-cell lung cancer (NSCLC) show promise in delaying resistance and brain progression. Optimizing treatment sequences with novel agents is key for advanced NSCLC patients.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • The treatment of non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations is rapidly evolving.
  • Classical EGFR mutations (exon 19 deletion, exon 21 L858R) represent a significant subset of NSCLC.
  • Current therapeutic strategies are being re-evaluated based on recent clinical trial data.

Purpose of the Study:

  • To review the current therapeutic landscape for EGFR-mutated NSCLC.
  • To discuss the implications of recent clinical trials (MARIPOSA, FLAURA 2) for first-line treatment strategies.
  • To explore emerging novel agents and the importance of treatment sequencing for pretreated patients.

Main Methods:

  • Review of landmark clinical trials, including MARIPOSA and FLAURA 2.
  • Analysis of data regarding combination therapies versus monotherapy.
  • Discussion of novel therapeutic agents and predictive biomarkers.

Main Results:

  • First-line combination strategies (lazertinib/amivantamab, chemotherapy/osimertinib) demonstrate potential to delay molecular resistance and intracranial progression compared to osimertinib monotherapy.
  • Novel agents like antibody-drug conjugates and bispecific antibodies offer new options for pretreated patients.
  • Patient and disease-specific factors, including central nervous system metastases, are critical for selecting first-line therapy.

Conclusions:

  • Optimizing first-line treatment selection based on patient and disease characteristics is crucial.
  • Strategic sequencing of therapies, including novel agents, is essential for improving outcomes in advanced EGFR-mutated NSCLC.
  • Further research into predictive biomarkers and biomarker-guided trials is needed to refine treatment strategies.

More Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.3K
Detection of Rare Mutations in CtDNA Using Next Generation Sequencing11:11

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

17.4K

Related Concept Videos

Mutations01:39

Mutations

Overview
94.5K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.5K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
Mutation, Gene Flow, and Genetic Drift01:09

Mutation, Gene Flow, and Genetic Drift

In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
64.2K
Mutations in Microorganisms01:18

Mutations in Microorganisms

Mutations are heritable changes in an organism’s genome involving alterations in the base sequence of DNA or RNA. These changes can influence cellular processes and phenotypic traits, potentially transforming the unaltered wild type into a mutant form. Such changes, termed forward mutations, are pivotal in shaping the genetic diversity of organisms.RNA viruses exhibit the highest mutation rates due to the absence of robust proofreading mechanisms during genome replication. In contrast,...
724
Point and Frameshift Mutations01:30

Point and Frameshift Mutations

Point mutations are genetic alterations involving the change of a single nucleotide base pair in DNA. Depending on how the alteration affects protein synthesis, they can lead to various consequences.Point mutations fall into the following types:Silent mutations occur when a nucleotide change does not alter the amino acid sequence due to the redundancy of the genetic code. For instance, changing ACC to ACA still encodes threonine, leaving the protein function unaffected. This occurs because...
1.2K